It has been a banner year for biotech buyouts, and these are two of the prime targets.

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

They have at least one thing in common: An exciting pipeline.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.

Kardigan (KARD) didn’t just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...